| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/AJT.13295 |
| P698 | PubMed publication ID | 25930984 |
| P50 | author | Denis Glotz | Q56859181 |
| John J Friedewald | Q42686679 | ||
| P2093 | author name string | R A Gordon | |
| A R Tambur | |||
| J R Leventhal | |||
| M F Cusick | |||
| K M K Haarberg | |||
| N D Herrera | |||
| P2860 | cites work | Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients | Q43681319 |
| HLA antibody specification using single-antigen beads--a technical solution for the prozone effect | Q43914521 | ||
| Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. | Q46367397 | ||
| Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. | Q47194132 | ||
| Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads | Q50618048 | ||
| Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. | Q53032138 | ||
| Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. | Q53244973 | ||
| The Clinical Spectrum ofDe NovoDonor-Specific Antibodies in Pediatric Renal Transplant Recipients | Q57521747 | ||
| HLA antibody detection with solid phase assays: great expectations or expectations too great? | Q27015921 | ||
| Complement is activated by IgG hexamers assembled at the cell surface | Q30409381 | ||
| Using real data for a virtual crossmatch | Q33467644 | ||
| Perception versus reality?: Virtual crossmatch--how to overcome some of the technical and logistic limitations | Q33888812 | ||
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients | Q36772957 | ||
| Quantifying HLA-specific antibodies in patients undergoing desensitization | Q37888424 | ||
| New approaches for detecting complement-fixing antibodies | Q38019743 | ||
| Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation | Q38120400 | ||
| Incidence and impact of de novo donor-specific alloantibody in primary renal allografts | Q39472834 | ||
| Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients | Q42656427 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 2421-2430 | |
| P577 | publication date | 2015-04-30 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information | |
| P478 | volume | 15 |
| Q46360525 | 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection |
| Q39105369 | Acute antibody-mediated rejection in kidney transplant recipients |
| Q47744928 | Acute rejection |
| Q38818993 | Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside |
| Q39612344 | Allelic and Epitopic Characterization of Intra-Kidney Allograft Anti-HLA Antibodies at Allograft Nephrectomy. |
| Q37252505 | Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor-Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching |
| Q89474375 | Anti-HLA-DQ antibodies are highly and independently related to the C1q-binding capacity of HLA antibodies |
| Q51278545 | Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies? |
| Q37441785 | Antibody-mediated Rejection in Lung Transplantation |
| Q94476124 | Antibody-mediated rejection after lung transplantation |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q39445381 | Application, technical issues, and interpretation of C1q for graft outcome |
| Q54589598 | Assignment of C1q-binding HLA antibodies as unacceptable HLA antigens avoids positive CDC-crossmatches prior to transplantation of deceased donor organs. |
| Q39384930 | Biomarkers to detect rejection after kidney transplantation. |
| Q40417954 | C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study |
| Q92712461 | Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays |
| Q52586350 | Clinical Utility of Complement-Dependent C3d Assay in Kidney Recipients Presenting with Late Allograft Dysfunction. |
| Q47147931 | Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies |
| Q38839248 | Clinically relevant interpretation of solid phase assays for HLA antibody |
| Q55509898 | Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome. |
| Q47646739 | Complement (C1q) Binding De Novo Donor Specific Antibodies and Cardiac-Allograft Vasculopathy in Pediatric Heart Transplant Recipients |
| Q54969814 | Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. |
| Q39928595 | De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation |
| Q38861456 | De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients. |
| Q48955987 | De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis |
| Q40468571 | De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability. |
| Q39221154 | Defining the immunogenicity and antigenicity of HLA epitopes is crucial for optimal epitope matching in clinical renal transplantation |
| Q55289737 | Depletion of donor-specific anti-HLA A2 alloantibodies in a hematopoietic cell transplant recipient using directed mismatched platelet transfusions. |
| Q47563660 | Desensitisation strategies in high-risk children before kidney transplantation. |
| Q64263915 | Detecting donor-specific antibodies: the importance of sorting the wheat from the chaff |
| Q39265221 | Donor-Specific Antibodies in Kidney Transplant Recipients |
| Q43110440 | Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients |
| Q58733582 | Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients |
| Q93035787 | EDTA Treatment for Overcoming the Prozone Effect and for Predicting C1q Binding in HLA Antibody Testing |
| Q51560504 | EDTA Treatment of Serum Unmasks Complement-Mediated Prozone Inhibition in Human Leukocyte Antigen Antibody Testing. |
| Q48336452 | EDTA is superior to DTT treatment for overcoming the prozone effect in HLA antibody testing |
| Q51563025 | Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. |
| Q39366464 | Evolving Approaches in the Identification of Allograft-reactive T and B Cells in Mice and Humans |
| Q37590820 | From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. |
| Q28074462 | HLA Mismatching Strategies for Solid Organ Transplantation - A Balancing Act |
| Q47667545 | How do I … manage the platelet transfusion-refractory patient? |
| Q42364236 | IgM-Enriched Human Intravenous Immunoglobulin-Based Treatment of Patients With Early Donor Specific Anti-HLA Antibodies After Lung Transplantation |
| Q91837466 | Immune Algorithm Optimization for Organ Transplantation in Poland |
| Q47130649 | Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome. |
| Q36269871 | Improvement in the definition of anti-HLA antibody profile in highly sensitized patients |
| Q36007256 | Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians |
| Q96648130 | Investigating complement mediated interference in class I HLA-specific antibodies following renal transplantation |
| Q99413308 | Investigating the relationship between class I HLA-specific immunoglobulin-G subclasses, Pan-IgG single antigen bead assays and complement mediated interference in sera from renal transplant recipients |
| Q51585363 | Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss. |
| Q50993047 | Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates |
| Q38773711 | Moving Biomarkers toward Clinical Implementation in Kidney Transplantation |
| Q51454635 | Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation. |
| Q64899061 | Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation. |
| Q40636545 | Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients |
| Q91532589 | Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients |
| Q52793674 | Proteasome Inhibitor Carfilzomib-Based Therapy for Antibody-Mediated Rejection of the Pulmonary Allograft: Use and Short-Term Findings. |
| Q52747059 | Prozone Effect Can Be Specific to Single Antigen Bead Kit Manufacturers. |
| Q41217311 | Quantitative Evaluation of the Impact of Ethylenediaminetetraacetic Acid Pretreatment on Single-Antigen Bead Assay |
| Q45057936 | Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. |
| Q104134305 | Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study |
| Q48223723 | Scandiatransplant acceptable mismatch program (STAMP) a bridge to transplanting highly immunized patients |
| Q38558820 | Sensitization assessment before kidney transplantation |
| Q90110720 | Serum dilutions as a predictive biomarker for peri-operative desensitization: An exploratory approach to transplanting sensitized heart candidates |
| Q37609092 | Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes |
| Q33760357 | Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies. |
| Q42174325 | The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. |
| Q30397251 | The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies |
| Q38960197 | The Road to HLA Antibody Evaluation: Do Not Rely on MFI. |
| Q38793606 | The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions |
| Q93065771 | The impact of alloantibodies directed against the second donor on long-term outcomes of repeat liver transplantation |
| Q48305003 | The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation. |
| Q64063924 | Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival |
| Q42402671 | Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation |
| Q38542338 | Transplant immuno-diagnostics: crossmatch and antigen detection |
| Q47920746 | Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. |
| Q50753647 | Unacceptable human leucocyte antigens: how to navigate between increased immunological risk and waiting time? |
| Q89049434 | Value of C3d assay and IgG subclass in the prediction of the flow cytometry cross-match result for renal transplantation |
| Q40634986 | Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss |
Search more.